Use of anti-CS1 antibodies for treatment of rare lymphomas

1. A method of treating NK cell lymphoma comprising, administering to a human patient in need thereof a therapeutically effective amount of an anti-CS1 antibody or antigen binding fragment thereof, or an anti-CS1 antibody-drug conjugate comprising anti-CS1 antibody or antigen binding fragment conjugated to a cytotoxic agent.

2. The method of claim 1 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, is administered as a monotherapy.

3. The method of claim 1 , further comprising administering to said patient a second therapeutic agent.

4. The method of claim 1 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, induces ADCC in cells of said lymphoma.

5. The method of claim 1 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, comprises heavy chain CDR sequences of SEQ ID NOS:11, 12 and 13 and light chain CDR sequences of SEQ ID NOS:14, 15 and 16.

6. The method of claim 1 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, comprises a heavy chain variable region of SEQ ID NO:9 and a light chain variable region of SEQ ID NO:10.

7. The method of claim 1 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, competes with the monoclonal antibody Luc63, as produced by the hybridoma deposited with the American Type Culture Collection (“ATCC”) and assigned accession no. PTA-5950, for binding to CS1.

8. The method of claim 1 , wherein said NK cell lymphoma is positive for CS1 expression.

9. The method of claim 8 , further comprising, prior to said administration, assaying said NK cell lymphoma for CS1 expression.

10. The method of claim 3 , wherein the second therapeutic agent is a radiotherapeutic.

11. The method of claim 10 , wherein the second therapeutic agent is a chemotherapeutic.

12. The method of claim 11 wherein the chemotherapeutic agent is a cytotoxic agent.

13. The method of claim 3 , wherein the second therapeutic agent is an anti-angiogenic agent.

14. The method of claim 3 , wherein the second therapeutic agent is a cytokine, a tyrosine kinase inhibitor, a kinase inhibitor, or an HDAC inhibitor.

15. The method of claim 3 , wherein the second therapeutic agent is a combination therapy.

16. The method of claim 15 , wherein the combination therapy is CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisone).

17. The method of claim 3 , wherein the anti-CS1 antibody and the second therapeutic agent are administered simultaneously, sequentially or separately.

18. A method of treating NK cell lymphoma, NK/T cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), or peripheral T cell lymphoma not otherwise specified (PTCL-NOS), comprising, administering to a human patient in need thereof a therapeutically effective amount of an anti-CS1 antibody or antigen binding fragment thereof, or an anti-CS1 antibody-drug conjugate comprising an anti-CS1 antibody or antigen binding fragment conjugated to a cytotoxic agent, wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, competes with monoclonal antibody Luc63, as produced by the hybridoma deposited with the American Type Culture Collection (“ATCC”) and assigned accession no. PTA-5950, for binding to CS1.

19. The method of claim 18 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, is administered as a monotherapy.

20. The method of claim 18 , further comprising administering to said patient a second therapeutic agent.

21. The method of claim 20 , wherein the second therapeutic agent is a radiotherapeutic.

22. The method of claim 21 , wherein the second therapeutic agent is a chemotherapeutic.

23. The method of claim 22 , wherein the chemotherapeutic agent is a cytotoxic agent.

24. The method of claim 18 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, induces ADCC in cells of said lymphoma.

25. The method of claim 18 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, comprises heavy chain CDR sequences of SEQ ID NOS:11, 12 and 13 and light chain CDR sequences of SEQ ID NOS:14, 15 and 16.

26. The method of claim 18 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, comprises a heavy chain variable region of SEQ ID NO:9 and a light chain variable region of SEQ ID NO:10.

27. A method of treating NK cell lymphoma, NK/T cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), or peripheral T cell lymphoma not otherwise specified (PTCL-NOS), comprising, administering to a human patient in need thereof a therapeutically effective amount of an anti-CS1 antibody or antigen binding fragment thereof, or an anti-CS1 antibody-drug conjugate comprising anti-CS1 antibody or antigen binding fragment conjugated to a cytotoxic agent, wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, competes with the monoclonal antibody Luc90, as produced by the hybridoma deposited with the ATCC and assigned accession no. PTA-5091, for binding to CS1.

28. The method of claim 27 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, is administered as a monotherapy.

29. The method of claim 27 , further comprising administering to said patient a second therapeutic agent.

30. The method of claim 29 , wherein the anti-CS1 antibody or antigen binding fragment thereof, or the anti-CS1 antibody-drug conjugate, induces ADCC in cells of said lymphoma.